THCA Shows Promise for Huntington’s Disease, Study Finds

Photo Credit: Leafly

Photo Credit: Leafly

In a new study published in the British Journal of Pharmacology, researchers have found THCA reduced inflammation, served as a neuroprotectant, improved motor function, and prevented brain degeneration in animals. THCA is the acidic precursor to THC, and is found in cannabis that has not yet undergone the heating process decarboxylation. THCA has the a lot of the same beneficial properties offered by THC, but without any psychoactive side effects. One thing that distinguishes THCA from other cannabinoids is its ability to positively affect the PPARy brain receptor, which is responsible for lipid metabolism and glucose homeostasis. This has led the study’s authors to believe THCA may serve “as a lead structure for the development of novel drugs for the management of (Huntington’s) and, possibly, other neurodegenerative and inflammatory diseases.” The authors find their study unique in that they are actively researching the acidic forms of cannabinoids, something that other studies often neglect. They explain most studies “have used neutral cannabinoids, especially THC and CBD… with little attention to the genuine phytocannabinoids of the plant, namely their acidic forms. We provide evidence that these compounds hold significant pharmacological potential.”

This information has been provided by Leafly and approve by our Chief Medical Officer.